Zealand Pharma slump wipes billions off its value after obesity drug data disappoints

Core Viewpoint - Zealand Pharma's shares fell over 30% following disappointing mid-stage trial results for its obesity drug petrelintide, leading to a significant loss in market value [1][1][1] Company Summary - Zealand Pharma's stock decline marks its worst trading day on record, with a market value loss of approximately 8.3 billion Danish crowns ($1.3 billion) [1][1][1] - The drug petrelintide demonstrated a weight loss of up to 10.7% over 42 weeks in a study involving 493 patients, which is below expectations compared to competitors [1][1][1] - The company is collaborating with Roche to develop petrelintide, which was described as a "nearly perfect fit" for competing in the obesity market [1][1][1] Industry Summary - The obesity drug market is highly competitive, with significant expectations for efficacy; rival treatments have shown higher weight loss percentages, such as Eli Lilly's drug candidate achieving up to 20.1% [1][1][1] - Recent setbacks in the industry, including Novo Nordisk's underperformance in a head-to-head trial, highlight the challenges faced by companies in this sector [1][1][1] - Analysts suggest that while petrelintide may have potential, it is likely to be viewed as a second-best option compared to Lilly's offerings, complicating its positioning in the market [1][1][1]